Core Viewpoint - The company has announced its third-quarter report for 2025, ensuring the accuracy and completeness of the financial information presented, and has made significant governance changes including the cancellation of the supervisory board and adjustments to the board of directors [8][11][13]. Financial Data - The third-quarter financial report is not audited, and the company has confirmed that the financial data is accurate and complete [3][5]. - The report includes major financial indicators and accounting data, although specific figures are not disclosed in the provided documents [3][4]. Governance Changes - The company has proposed to cancel the supervisory board and adjust the number of directors, which requires shareholder approval [13][16]. - The board has also approved amendments to the company's articles of association and governance rules in light of these changes [16][22]. Shareholder Meeting - A temporary shareholder meeting is scheduled for November 17, 2025, to discuss the proposed governance changes and other matters [63][64]. - The meeting will utilize both in-person and online voting methods to facilitate participation [65][66]. International Expansion - The company plans to sign a distribution and marketing agreement with Helios and Early Morning International for its product Efparepoetin alfa in Vietnam, aiming to enhance its international market presence [47][48]. - This agreement is part of the company's strategy to internationalize its products and improve brand influence [60]. Product Development - The product Efparepoetin alfa is a recombinant fusion protein aimed at treating anemia in chronic kidney disease patients and is currently under development with significant R&D investment [50][51]. - The company has invested approximately 51.24 million yuan in the development of this product as of September 30, 2025 [51].

Core Viewpoint - The company has signed a distribution, marketing service, and agency agreement with Helios and Zaoan International for the exclusive marketing and distribution of injectable Efparepoetin alfa in targeted regions, which is a new Class I biopharmaceutical drug for treating anemia in adult dialysis patients due to chronic kidney disease (CKD) [1] Group 1 - The subsidiary Luzhou Buchang will authorize Helios to carry out exclusive marketing and distribution of injectable Efparepoetin alfa [1] - Injectable Efparepoetin alfa is intended for adult dialysis patients undergoing erythropoietin therapy due to anemia caused by chronic kidney disease [1] - The drug has already submitted a market application for approval [1]

Core Viewpoint - The company, Buchang Pharma, is expanding its market presence in Vietnam through a distribution agreement for its product Efparepoetin alfa, which is aimed at treating anemia in adult dialysis patients with chronic kidney disease [1] Company Summary - Buchang Pharma's subsidiary, Luzhou Buchang, plans to sign a distribution and marketing agreement with Helios and Aozan International in Vietnam [1] - Helios will act as the exclusive distributor in the region, while Aozan International will serve as an intermediary [1] - The product Efparepoetin alfa is specifically indicated for adult dialysis patients undergoing erythropoietin treatment due to anemia caused by chronic kidney disease [1] Financial Summary - In the third quarter of 2025, Buchang Pharma reported a net profit attributable to shareholders of 241 million yuan, representing a year-on-year increase of 195.44% [1]